世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000027635

次世代がん診断:技術と世界市場

BCC Research

Next Generation Cancer Diagnostics: Technologies and Global Markets

発刊日2020/09/01

言語英語

体裁PDF/318ページ

「PDF」版318ページ

0000027635

次世代がん診断:技術と世界市場
Next Generation Cancer Diagnostics: Technologies and Global Markets

5,500 USD

※商品のお問い合わせはカートに入れていただくと可能です。

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。他のライセンス形態・価格に関しましてはご相談下さい。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

次世代がん診断の世界市場は2020年の62億ドルから2025年までに167億ドルに拡大する見込みで、2020−2025年におけるCAGRは21.9%と推定されます。

レポートの内容

  • 22のデータ表に74の表を追加
  • 次世代がん診断の世界市場と技術の概要
  • 2019年のデータ、2020年の推定、2025年までのCAGR予測による世界市場の動向分析
  • がんの部位別、分析目的別、分析プラットフォーム別、地域別、次世代がん診断市場の分析、
  • アレイおよびマイクロフルイディクス(LOAC)技術、マルチプレックス従来型アッセイ技術、次世代シーケンシング技術、ポリメラーゼ連鎖反応(PCR)技術について
  • 現在の市場動向、市場規模、市場予測、新製品のパイプライン分析、がん診断市場の規制シナリオ
  • がん診断のニーズ、規制動向、業界構造、特許の権利状況などに影響を及ぼす要因について
  • 次世代がん診断市場に関連した主な取組みやプログラムの詳細情報
  • Abbott Laboratories, Illumina Inc., Myriad Genetics Inc., Qiagen NV, Oche Holding AG, and Thermo Fisher Scientific Inc.などの主要企業の市場シェア分析、それらの戦略的プロファイリング、競争環境、詳細な企業プロフィール

レポート詳細

章ごとの価格

このレポートは章ごとの個別販売も行っております。
以下の章ごとの価格は予期せず変更となる可能性がありますので、お問い合わせ下さい。
Chapter1 ご希望の方も、お問い合わせ下さい。
※全てPDFでの販売となります。

Title / Chapter Name Pages Price
Full Report: Next Generation Cancer Diagnostics: Technologies and Global Markets 318 $5,500
Chapter- 1: Introduction 9 Free
Chapter- 2: Summary and Highlights 4 $250
Chapter- 3: Overview 7 $121
Chapter- 4: Technologies 13 $225
Chapter- 5: Liquid Biopsy Technologies 16 $277
Chapter- 6: Next Generation Cancer Diagnostics: Key Initiatives and Programs 15 $259
Chapter- 7: Next Generation Cancer Diagnostic Applications by Cancer Site 57 $986
Chapter- 8: Cancer Diagnostics Industries 30 $519
Chapter- 9: Industry Acquisitions and Strategic Alliances 9 $156
Chapter- 10: Cancer Diagnostics Markets 64 $1,107
Chapter- 11: Patents 5 $86
Chapter- 12: Company Profiles 89 $1,539

目次

Chapter- 1: Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

Chapter- 2: Summary and Highlights
Table Summary : Global Market for Next Generation Cancer Diagnostics, by Cancer Site, Through 2025
Figure Summary : Global Market for Next Generation Cancer Diagnostics, by Cancer Site, 2019-2025

Chapter- 3: Overview
Large-Scale Initiatives and Consortia
Market Size
Liquid Biopsy as a Market Driving Force
Key Trends
Industry
BCC Research Select Insights from Industry Leaders
Table 1 : Next Generation Cancer Diagnostics: Scope of Report

Chapter- 4: Technologies
Diagnostics Overview
Arrays and Microfluidics (LOAC) Technologies
Multiplex Conventional Technologies
Next Generation Sequencing Technology
Polymerase Chain Reaction (PCR) Technology

Chapter- 5: Liquid Biopsy Technologies
Liquid Biopsy Biomarkers
Cancer Genomics
Circulating Tumor Cell Technologies
CTC Workflow
Cell Isolation Technologies
CTC Sample Preparation Technologies
CTC Downstream Analysis Technologies
Comparison of Liquid Biopsy with Conventional Biopsy
Cancer Testing
Avatar-Driven Diagnostic Approaches

Chapter- 6: Next Generation Cancer Diagnostics: Key Initiatives and Programs
Blood Profiling Atlas
Cancer-ID
Cancer Moon Shots
China Precision Medicine Initiative
ClinGen
CTC Trap Consortium
Early Cancer Detection Consortium
EpiFemCare
France Genomic Medicine Plan
Friends of Cancer Research Project
Human Cell Atlas
Immunomonitor Consortium
Integration of Imaging and Fluid-Based Tumor Monitoring
Liquid Biopsies and Imaging for Improved Cancer Care
Million Veteran Program
MedSeq
Next-Generation Single-Cell Analysis Program
Population Sequencing Projects
Precancer Atlas
Precision Medicine Initiative
Prompt
QuIP Project
Single-Cell Proteomics and Lipidomics Project
TopMed
Treehouse Childhood Cancer Initiative
Very Rare Cancer Consortium
Worldwide Innovative Networking (WIN) Consortium
Single-Cell Research
Population Sequencing Programs
Table 32 : R&D: Next Generation Cancer Diagnostics

Chapter- 7: Next Generation Cancer Diagnostic Applications by Cancer Site
Introduction
Bladder Cancer
Brain Cancer
Breast Cancer
Gynecologic Cancers
Colorectal Cancer
Cancer Unknown Primary
Gastric Cancer
Kidney Cancer
Hematologic Tests: Leukemia and Myeloma
Liver Cancer
Lung Cancer
Hematologic Tests: Lymphomas
Melanoma
Pan-Cancer
Prostate Cancer
Thyroid Cancer

Chapter- 8: Cancer Diagnostics Industries
Sequencing Instruments Industry
Long Read Sequencing Industry
Sequencing Informatics Industry
PCR Industry
Droplet Digital PCR Industry
CTC Capture and Detection Industry
Liquid Biopsy Assay Industry

Chapter- 9: Industry Acquisitions and Strategic Alliances
Acquisitions
Strategic Alliances

Chapter- 10: Cancer Diagnostics Markets
Forces Driving Growth
COVID-19 Impact on Cancer Diagnostic Markets
Cancer Markets
Market for Next Generation Cancer Diagnostics by Cancer Site
Market for Next Generation Cancer Diagnostics by Purpose of Analysis
Market for Next Generation Cancer Diagnostics by Test Platform
Market for Test Platforms by Cancer Site
Market by Diagnostic Segment
Regional Market Analysis

Chapter- 11: Patents
Circulating Tumor Cell Patents
Exosome Patents
Cell-free DNA (cfDNA) Patents
Biomarker-Related Patents
Patent Considerations: AI in Cancer Diagnostics

Chapter- 12: Company Profiles
20/20 GENE SYSTEMS
ABBOTT LABORATORIES
ADAPTIVE BIOTECHNOLOGIES INC.
AGENDIA NV
AGILENT TECHNOLOGIES INC.
AKADEUM LIFE SCIENCES
AMBRY GENETICS
AMOY DIAGNOSTICS CO. LTD.
ANGLE PLC
APOCELL INC.
APOSTLE INC.
ARBOR VITA CORP.
ARCHER DX
AROCELL AB
ARUP LABORATORIES
ASPIRA LABS
ASURAGEN, INC.
ATILA BIOSYSTEMS
AVIVA BIOSCIENCES
BECTON, DICKINSON AND CO.
BGI SHENZHEN
BIOCARTIS NV
BIOCEPT INC.
BIODESIX INC.
BIOFIDELITY LTD.
BIOFLUIDICA INC.
BIOLIDICS LTD.
BIOLOGICAL DYNAMICS INC.
BIOPROGNOS SL
BIOTHERANOSTICS INC.
BIO-TECHNE CORP.
BLUESTAR GENOMICS INC.
CANCER GENETICS INC.
CARIS LIFE SCIENCES
CASTLE BIOSCIENCES INC.
CC DIAGNOSTICS BV
CELCUITY INC.
CELLMAX LIFE
CELLULAR ANALYTICS
CELL MICROSYSTEMS INC.
CELSEE DIAGNOSTICS
CHIP DIAGNOSTICS
CHRONIX BIOMEDICAL
CIRCULOGENE THERANOSTICS
CLINICAL GENOMICS TECHNOLOGIES
CODIAK BIOSCIENCES
DANAHER CORP.
DECIPHER BIOSCIENCES
DERMTECH
DIACARTA INC.
DNALYTICS
EPIGENOMICS AG
EPIC SCIENCES INC.
EXACT SCIENCES CORP.
FLUXION BIOSCIENCES INC.
FREENOME INC.
FULGENT GENETICS INC.
GENECENTRIC THERAPEUTICS
GENEDX INC.
GENERA BIOSYSTEMS
GENESEQ BIOSCIENCES PTY LTD.
GENETRON HEALTH TECHNOLOGIES INC.
GENEOSCOPY LLC
GENEXOSOME TECHNOLOGIES INC.
GRAIL INC.
GUARDANT HEALTH INC.
HOLOGIC INC.
HTG MOLECULAR DIAGNOSTICS INC.
IDL BIOTECH
ILLUMINA INC.
IMMUNIS AI
INCELLDX INC.
INIVATA LTD.
INTERPACE BIOSCIENCES INC.
INVITAE INC.
INVIVOSCRIBE INC.
JBS SCIENCE INC.
LABORATORY CORP. OF AMERICA INC.
LEXENT BIO INC.
LUCENCE DIAGNOSTICS PTE. LTD.
LUNGLIFE AI, INC.
MDNA LIFE SCIENCES INC.
MDXHEALTH INC.
MEDGENOME INC.
MENARINI SILICON BIOSYSTEMS SPA
MIRADX
MIR SCIENTIFIC
MUTANTDX
MY PERSONAL THERAPEUTICS LTD.
MYRIAD GENETICS INC.
NEOGENOMICS LABORATORIES
NEO NEW ONCOLOGY GMBH
NODEXUS
NOVIGENIX SA
NRICH DX
NUCLEIX
NUPROBE INC.
ONCIMMUNE HOLDINGS PLC
ONCOCYTE CORP.
ONCODNA S.A.
OPKO HEALTH
OXFORD GENE TECHNOLOGY
PACIFIC EDGE LTD.
PANGAEA LABORATORY
PANGAEA ONCOLOGY
PERSONAL GENOME DIAGNOSTICS INC.
POLYMEDCO, INC.
PREDICINE INC.
PROVISTA DIAGNOSTICS INC.
QIAGEN NV
QUANTUMDX
QUEST DIAGNOSTICS INC.
RARECYTE INC.
RESOLUTION BIOSCIENCE INC.
ROCHE HOLDING AG
SAGA DIAGNOSTICS AB
SANOMICS LTD.
SIENNA CANCER DIAGNOSTICS LTD.
SINGLERA GENOMICS INC.
SISTEMAS GENOMICOS
SKYLINEDX BV
STAGE ZERO LIFE SCIENCES
STRAND LIFE SCIENCES PVT., LTD.
SYSMEX INOSTICS GMBH
THERMO FISHER SCIENTIFIC INC.
THRIVE EARLIER DETECTION CORP.
TIZIANA LIFE SCIENCES PLC
VORTEX BIOSCIENCES
VERACYTE
VOLITIONRX
XING TECHNOLOGIES LLC
YIKON GENOMICS CO. LTD.

この商品のレポートナンバー

0000027635

TOP